tired on glp 1 GLP-1 Fatigue: Why It Happens and What Gently Helps How to Handle Fatigue on

Safety and Clinical Management Safety trials of GLP-1 RAs, including liraglutide, tirzepatide, and semaglutide (oral or subcutaneous), indicate that the most common adverse events (AEs) of treatment are mild to moderate gastrointestinal including nausea, vomiting, diarrhea, constipation, dyspepsia, and decreased appetite

They provide an anti-inflammatory benefit, largely because they help reduce visceral (intra-abdominal) fat, which is itself, highly inflammatory tissue

Patients can expect to lose several pounds a week on Ozempic in most cases, meaning monthly weight loss can be up to ten pounds or more

Gastrointestinal issues are usually strongest in first-time users, or when people step up to a larger dosage, but they usually dissipate over time

21 August 2020 [Initial approval 4 January 2018]